
TY  - JOUR
AU  - Gey, A.
AU  - Tadie, J.-M.
AU  - Caumont-Prim, A.
AU  - Hauw-Berlemont, C.
AU  - Cynober, L.
AU  - Fagon, J.-Y.
AU  - Terme, M
AU  - Diehl, J.-L.
AU  - Delclaux, C.
AU  - Tartour, E.
TI  - Granulocytic myeloid-derived suppressor cells inversely correlate with plasma arginine and overall survival in critically ill patients
JO  - Clinical & Experimental Immunology
JA  - Clin Exp Immunol
VL  - 180
IS  - 2
SN  - 0009-9104
UR  - https://doi.org/10.1111/cei.12567
DO  - doi:10.1111/cei.12567
SP  - 280
EP  - 288
KW  - arginine
KW  - biomarker
KW  - critically ill patients
KW  - granulocytic myeloid-derived suppressor cells (gMDSC)
KW  - immunosuppression
PY  - 2015
AB  - Summary Critically ill patients display a state of immunosuppression that has been attributed in part to decreased plasma arginine concentrations. However, we and other authors have failed to demonstrate a clinical benefit of L-arginine supplementation. We hypothesize that, in these critically ill patients, these low plasma arginine levels may be secondary to the presence of granulocytic myeloid-derived suppressor cells (gMDSC), which express arginase known to convert arginine into nitric oxide (NO) and citrulline. Indeed, in a series of 28 non-surgical critically ill patients, we showed a dramatic increase in gMDSC compared to healthy subjects (P?=?0·0002). A significant inverse correlation was observed between arginine levels and gMDSC (P?=?0·01). As expected, gMDSC expressed arginase preferentially in these patients. Patients with high gMDSC levels on admission to the medical intensive care unit (MICU) presented an increased risk of death at day 7 after admission (P?=?0·02). In contrast, neither plasma arginine levels, monocytic MDSC levels nor neutrophil levels were associated with overall survival at day 7. No relationship was found between body mass index (BMI) or simplified acute physiology score (SAPS) score, sequential organ failure assessment (SOFA) score or gMDSC levels, eliminating a possible bias concerning the direct prognostic role of these cells. As gMDSC exert their immunosuppressive activity via multiple mechanisms [production of prostaglandin E2 (PGE2), interleukin (IL)-10, arginase, etc.], it may be more relevant to target these cells, rather than simply supplementing with L-arginine to improve immunosuppression and its clinical consequences observed in critically ill patients.
ER  - 

TY  - JOUR
TI  - Static Poster Abstracts
JO  - Nephrology
JA  - Nephrology
VL  - 21
IS  - S2
SN  - 1320-5358
UR  - https://doi.org/10.1111/nep.12888
DO  - doi:10.1111/nep.12888
SP  - 150
EP  - 280
PY  - 2016
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Alcoholism: Clinical and Experimental Research
VL  - 14
IS  - 2
SN  - 0145-6008
UR  - https://doi.org/10.1111/j.1530-0277.1990.tb00486.x
DO  - doi:10.1111/j.1530-0277.1990.tb00486.x
SP  - 264
EP  - 356
PY  - 1990
ER  - 

TY  - JOUR
TI  - ePresentation Sessions
JO  - European Journal of Neurology
JA  - Eur J Neurol
VL  - 26
IS  - S1
SN  - 1351-5101
UR  - https://doi.org/10.1111/ene.14018
DO  - doi:10.1111/ene.14018
SP  - 112
EP  - 346
PY  - 2019
ER  - 

TY  - JOUR
TI  - Abstracts accepted for publication only
JO  - Clinical Microbiology and Infection
VL  - 13
IS  - s1
SN  - 1198-743X
UR  - https://doi.org/10.1111/j.1469-0691.2007.01734.x
DO  - doi:10.1111/j.1469-0691.2007.01734.x
SP  - S609
EP  - S676
PY  - 2007
ER  - 

TY  - JOUR
TI  - Poster abstracts
JO  - HIV Medicine
VL  - 7
IS  - s1
SN  - 1464-2662
UR  - https://doi.org/10.1111/j.1464-2662.2006.00375.x
DO  - doi:10.1111/j.1464-2662.2006.00375.x
SP  - 11
EP  - 38
PY  - 2006
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Mycoses
VL  - 55
IS  - s4
SN  - 0933-7407
UR  - https://doi.org/10.1111/j.1439-0507.2012.02206.x
DO  - doi:10.1111/j.1439-0507.2012.02206.x
SP  - 95
EP  - 338
PY  - 2012
ER  - 

TY  - JOUR
TI  - Posters (Abstracts 301–2389)
JO  - Hepatology
JA  - Hepatology
VL  - 68
IS  - S1
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.30257
DO  - doi:10.1002/hep.30257
SP  - 184
EP  - 1353
PY  - 2018
ER  - 

TY  - JOUR
TI  - POSTERS
JO  - Journal of the European Academy of Dermatology and Venereology
VL  - 12
IS  - s2
SN  - 0926-9959
UR  - https://doi.org/10.1111/j.1468-3083.1999.tb00920.x
DO  - doi:10.1111/j.1468-3083.1999.tb00920.x
SP  - S141
EP  - S355
PY  - 1999
ER  - 

TY  - JOUR
TI  - 14th ISN MEETING, MONTPELLJER, FRANCE
JO  - Journal of Neurochemistry
VL  - 61
IS  - s1
SN  - 0022-3042
UR  - https://doi.org/10.1111/j.1471-4159.1993.tb13441.x
DO  - doi:10.1111/j.1471-4159.1993.tb13441.x
SP  - 1
EP  - 285
PY  - 1993
ER  - 

TY  - JOUR
TI  - Bristol Cup Posters: Summaries of Posters
JO  - British Journal of Dermatology
VL  - 155
IS  - s1
SN  - 0007-0963
UR  - https://doi.org/10.1111/j.1365-2133.2006.07253.x
DO  - doi:10.1111/j.1365-2133.2006.07253.x
SP  - 21
EP  - 61
PY  - 2006
ER  - 

TY  - JOUR
TI  - Abstracts from the Scandinavian Society of Anesthesiology and Intensive Care Medicine 34th Congress
JO  - Acta Anaesthesiologica Scandinavica
JA  - Acta Anaesthesiol. Scand.
VL  - 61
IS  - 8
SN  - 0001-5172
UR  - https://doi.org/10.1111/aas.12941
DO  - doi:10.1111/aas.12941
SP  - 962
EP  - 1062
PY  - 2017
ER  - 

TY  - JOUR
TI  - Scientific Section
JO  - Transfusion
VL  - 43
IS  - 9s
SN  - 0041-1132
UR  - https://doi.org/10.1046/j.1537-2995.43.9s.6.x
DO  - doi:10.1046/j.1537-2995.43.9s.6.x
SP  - 1A
EP  - 130A
PY  - 2003
ER  - 

AU  - Soukup, Jason
AU  - Lewis, John
C7  - pp. 131-153
TI  - Oral and Maxillofacial Tumors, Cysts, and Tumor-Like Lesions
SN  - 9781118816127
UR  - https://doi.org/10.1002/9781118816219.ch7
DO  - doi:10.1002/9781118816219.ch7
SP  - 131-153
KW  - bone-associated lesions
KW  - incisional biopsy
KW  - malignant melanoma
KW  - maxillofacial tumors
KW  - non-odontogenic tumors
KW  - odontogenic cysts
KW  - odontogenic tumors
KW  - ossifying fibroma
KW  - squamous cell carcinoma
KW  - tumor-like lesions
PY  - 2003
AB  - Summary This chapter reviews the important clinical information of maxillofacial tumors, cysts, and tumor-like lesions of dogs and cats, including odontogenic tumors, non-odontogenic tumors, odontogenic cysts, bone-associated lesions, and tumor-like lesions of the gingiva and oral mucosa. Staging and incisional biopsy techniques are also discussed. Incisional biopsy is an important first step to discern the biological behavior of an oral tumor and treatment options. Malignant melanoma (MM) is the most common oral and maxillofacial tumor in dogs, but oral MM is rare in cats. Squamous cell carcinoma (SCC) is the most common oral tumor in cats and the second most common malignant oral tumor in dogs. The ossifying fibroma is a benign non-odontogenic, fibro-osseous lesion composed of fibrous, osseous, and sometimes cementum-like tissue. Odontogenic cysts are broadly classified as developmental or inflammatory cysts. Developmental cysts include dentigerous (follicular) cysts, lateral periodontal cysts and gingival cysts.
ER  - 

TY  - JOUR
TI  - Research Podium Abstracts
JO  - Value in Health
VL  - 11
IS  - 6
SN  - 9781118816127
UR  - https://doi.org/10.1111/j.1524-4733.2008.00453_1.x
DO  - doi:10.1111/j.1524-4733.2008.00453_1.x
SP  - A335
EP  - A362
PY  - 2008
ER  - 

TY  - JOUR
TI  - Research Poster Abstracts
JO  - Value in Health
VL  - 11
IS  - 6
SN  - 9781118816127
UR  - https://doi.org/10.1111/j.1524-4733.2008.00453_2.x
DO  - doi:10.1111/j.1524-4733.2008.00453_2.x
SP  - A362
EP  - A659
PY  - 2008
ER  - 

AU  - Meister, Edward A.
AU  - Kaplan, Bruce
C7  - pp. 1622-1637
TI  - Comparative Effectiveness in Transplantation
SN  - 9781118870143
UR  - https://doi.org/10.1002/9781118873434.ch135
DO  - doi:10.1002/9781118873434.ch135
SP  - 1622-1637
KW  - health services and outcomes research
KW  - organ transplantation in general
KW  - research methodology
KW  - economics
KW  - hospital discharge
KW  - hospital readmission
KW  - statistics
PY  - 2008
AB  - Summary Comparative effectiveness research (CER) refocuses medical research to manifest greater practical utility in the treatment of patients by comparing the relative benefits, harms, quality of life, utility gains, and cost-effectiveness of medical therapies. In contrast to random clinical trials, CER's goal is to heighten clinical effectiveness by emphasizing external validity and thus rendering more practical results. CER includes use of innovative research designs such as N-of-1 study designs, flexible observational data-driven studies, meta-analyses, and large data registries. CER employs extensive use of cost-utility-effectiveness analyses, which compare the quality of adjusted-life gains for medical interventions and the relative improvement in costs, by incremental-cost-utility analysis. Utilities are obtained using techniques like time-trade-off (TTO), standard gamble (SG), and visual analogue scales (VAS), or using standardized health indexes; SF-36, EQ-5D, or HUI-3. CER in transplantation research will play an important role as it seeks to advance knowledge of transplant effectiveness and patient-centered results by adding quality of adjusted-life assessments to augment the transplant decisional pathway.
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Epilepsia
JA  - Epilepsia
VL  - 60
IS  - S2
SN  - 9781118870143
UR  - https://doi.org/10.1111/epi.16336
DO  - doi:10.1111/epi.16336
SP  - 5
EP  - 248
PY  - 2019
ER  - 

TY  - JOUR
TI  - Contributed Podium Presentations
JO  - Value in Health
VL  - 10
IS  - 6
SN  - 9781118870143
UR  - https://doi.org/10.1111/j.1524-4733.2007.00263_1.x
DO  - doi:10.1111/j.1524-4733.2007.00263_1.x
SP  - A221
EP  - A242
PY  - 2007
ER  - 

TY  - JOUR
TI  - Supplement Article
JO  - British Journal of Haematology
JA  - Br J Haematol
VL  - 185
IS  - S1
SN  - 9781118870143
UR  - https://doi.org/10.1111/bjh.15854
DO  - doi:10.1111/bjh.15854
SP  - 3
EP  - 202
PY  - 2019
ER  - 
